TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$80 Million

Twist Bioscience Corporation

Initial Public Offering

Bookrunner, October 2018

Twist Bioscience Corporation
Twist is a leading and rapidly growing synthetic biology company that has developed a disruptive, scalable DNA synthesis platform targeted at diverse end markets. The core of Twist’s platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip to create synthetic DNA — a critical building block for the emerging field of synthetic biology. The Company has combined this technology with proprietary software and scalable commercial infrastructure to create an integrated platform that enables high levels of quality, precision, automation and manufacturing throughput at a significantly lower cost relative to competitors. The ability to modify DNA and design biological systems is the foundation for a rapidly growing set of synthetic biology products, applications and markets with an estimated potential user base of >100,000 spanning multiple industries, including healthcare, industrial chemicals, agriculture, academic research, and technology.